Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2% – Still a Buy?

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded up 9.2% on Wednesday . The company traded as high as $19.36 and last traded at $19.6830. 262,952 shares traded hands during trading, a decline of 91% from the average daily volume of 3,058,489 shares. The stock had previously closed at $18.02.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SRPT shares. HC Wainwright reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Piper Sandler lowered their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Thursday, July 9th. Weiss Ratings downgraded Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $25.06.

Sarepta Therapeutics Stock Performance

The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The firm’s fifty day moving average price is $17.17 and its 200-day moving average price is $18.31. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -6.74, a PEG ratio of 0.24 and a beta of 0.24.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same period last year, the business earned $2.02 EPS. Sarepta Therapeutics’s revenue for the quarter was down 34.3% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in SRPT. BlackRock Inc. acquired a new position in Sarepta Therapeutics during the second quarter worth approximately $341,339,000. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 454.6% in the fourth quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the period. First Trust Advisors LP grew its position in shares of Sarepta Therapeutics by 107.6% during the first quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock worth $89,995,000 after acquiring an additional 2,143,211 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Sarepta Therapeutics during the second quarter worth approximately $36,946,000. Finally, Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 9.2% in the 4th quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock valued at $254,167,000 after acquiring an additional 993,283 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.